CTOs on the Move

Ligand

www.ligand.com

 
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ligand.com
  • 3911 Sorrento Valley Boulevard
    San Diego, CA USA 92121
  • Phone: 858.550.7500

Executives

Name Title Contact Details

Similar Companies

Atalanta Therapeutics

Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases. Our founders` groundbreaking discoveries in RNA interference offer a powerful therapeutic approach to halt diseases at their source.

Lower Valley Ambulance

Lower Valley Ambulance is a Cheswick, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aldeyra Therapeutics, Inc

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.

Lynxcom Partners

Lynxcom Partners LLC is a Del Mar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Palladio Biosciences

Palladio Biosciences, Inc., a private, venture capital-backed biotech company, was founded in 2015 to develop transformative medicines for orphan diseases of the kidney.